Phase 2 N=114 New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
Diabetes Mellitus, Type 1
Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
N/A N=252 Assessment of Pain in People With Thalassemia
Thalassemia
Primary: Prevalence of Pain — 75; 7; 11 participants — p=0.45
N/A N=32 Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Thalassemia
Primary: Report of Pain by Age Group — 23; 61; 18; 51 percentage of participant-cycles — p=<.001
Phase 3 N=27 Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
Thalassemia · Hypertension, Pulmonary
Primary: Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group — -1.38 meters — p=0.97
Phase 2 N=30 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Thalassemia Major
Primary: Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC) — -5.934 % change of hematocrit-adjusted volume
Phase 2 N=7 A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
Beta-Thalassemia Major · Sickle Cell Disease
Primary: Number of Treated Participants With Successful Neutrophil and Platelet Engraftment — 3; 4; 3; 4 Participants
N/A N=38 Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Atrial Fibrillation
Primary: Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise — -10; -13 beats per minute
Phase 2 N=172 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
Multiple Sclerosis
Primary: Double Blind Period: Percentage of Participants With Grade 3 or 4 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) Hematological or Liver Toxicity — 63.71…
Phase 4 N=100 Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.
Chronic Heart Failure
Primary: Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or…
Phase 2 N=166 Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
Non-transfusion Dependent Thalassemia
Primary: Core Study: Change in Liver Iron Concentration (LIC) From Baseline to Week 52 — -1.95; -3.80; 0.38 mg iron (Fe)/g dry weight (dw)
Phase 2 N=21 Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
Severe Thalassemia
Primary: Primary Objective: Event-free Survival at 1 Year. — 17 Participants
Phase 3 N=555 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
Transfusional Iron Overload in β-thalassemia
Primary: Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event — 109; 113; 85; 110 Participants
Phase 3 N=24 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
Beta-Thalassemia
Primary: Percentage of Participants Who Meet the Definition of Transfusion Independence (TI) — 91.3 Percentage of participants
N/A N=13 Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
Type 2 Diabetes · Oxidative Stress
Primary: Fasting Urine F2 Alpha Isoprostane Levels — -0.089 ng/ml